Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukaemia.

G Dighiero1, T J Hamblin

  • 1Institut Pasteur de Montevideo, Montevideo, Uruguay.

Lancet (London, England)
|March 25, 2008
PubMed
Summary
This summary is machine-generated.

Chronic lymphocytic leukaemia (CLL) is a common blood cancer in older adults with variable outcomes. Advances in molecular markers improve prognosis assessment, but CLL remains incurable despite new treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Problems of Anticoagulant Control-II, Which Test?

Bristol medico-chirurgical journal (1963)·2017
Same author

Monoclonal and/or Oligoclonal Immunoglobulins in Sera of Patients with Non-Hodgkin's Lymphomas, Determined by Iso-Electric Focusing and Immunoblotting.

Leukemia & lymphoma·2016
Same author

B Cell Malignancies Frequently Target the Autoreactive B Cell Repertoire.

Leukemia & lymphoma·2016
Same author

CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3.

Leukemia & lymphoma·2016
Same author

Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.

Leukemia·2014
Same author

"Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''.

Blood cancer journal·2013
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Europe and North America, primarily affecting older adults.
  • CLL exhibits a highly variable clinical course, with patient survival ranging from months to decades.
  • Despite advances, CLL remains an incurable malignancy, with most patients experiencing relapse after treatment.

Purpose of the Study:

  • To review recent progress in identifying molecular and cellular markers for predicting CLL disease progression.
  • To discuss how a deeper understanding of B-cell receptor function, genetic lesions, and apoptosis influences prognosis and management.
  • To explore the impact of new therapeutic agents on the rational and effective management of CLL.

Main Methods:

Related Experiment Videos

  • Review of current literature on molecular and cytogenetic markers in CLL.
  • Analysis of the role of B-cell receptor signaling, genetic mutations, and apoptosis in CLL pathogenesis.
  • Evaluation of the efficacy of novel therapeutic agents in managing CLL.

    • Main Results:

    • Immunoglobulin gene mutational profile and cytogenetic abnormalities are key prognostic predictors in CLL.
    • Understanding B-cell receptor function, genetic lesions, and apoptosis provides insights into disease progression.
    • New therapeutic agents have improved the rationality and effectiveness of CLL management, though a cure is not yet achieved.

    Conclusions:

    • Molecular and cellular markers significantly enhance prognostic assessment for chronic lymphocytic leukaemia.
    • While treatments are more effective, chronic lymphocytic leukaemia remains a challenging, incurable disease.
    • Further research into CLL pathophysiology and novel therapies is crucial for improving patient outcomes.